This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

51/100

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β 1-42 , tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.

Key findings

The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling.
Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.

Why it matters

These consensus recommendations support using CSF amyloid-β 1-42, tau and phosphorylated tau in the diagnostic workup of mild cognitive impairment to predict decline or conversion to Alzheimer's dementia and guide management. They address diagnosis and prognosis only, not treating, curing or preventing the disease.

Study details

Evidence strengthLow

How this study scored 51/100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record	2 / 4	Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	2 / 5	2017 — within 10 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	5 / 7	Cited 142 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	12.9 citations a year over 11 year(s) since 2017
Impact for its field and year	4 / 6	Cited 11.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	3 / 6	Cited by 12 other studies in this library
Still being cited	2 / 4	Cited 26 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Gunhild Waldemar: h-index 80 (OpenAlex, whole career)
Institution's track record	2 / 3	University College London: institution h-index 2,029 (OpenAlex)
Multi-centre collaboration	3 / 3	OpenAlex lists 36 institution(s) in 14 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 28341066)
Free to read	0 / 2	Behind a paywall — scores zero
Total	51 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Herukka, S. K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., et al. (2017). Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1016/j.jalz.2016.09.009

Vancouver

Herukka SK, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, Blennow K, et al. Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2017. doi:10.1016/j.jalz.2016.09.009. PMID: 28341066.

BibTeX

@article{herukka2017-28341066,
  author  = {Herukka, S. K. and Simonsen, A. H. and Andreasen, N. and Baldeiras, I. and Bjerke, M. and Blennow, K. and Engelborghs, S. and Frisoni, G. B. and others},
  title   = {{Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2017},
  doi     = {10.1016/j.jalz.2016.09.009},
  pmid    = {28341066},
  url     = {https://doi.org/10.1016/j.jalz.2016.09.009}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 23.

Later studies that cite this one

12 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Mild cognitive impairment

Also tagged “biomarkers”

821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →